Pieris are easy-to-grow and cold-hardy evergreen shrubs with dark fingered foliage that is attractive all year round. This plant (also known as the andromeda bush or the lily-of-the-valley bush) ...

Pieris' PIRS shares were up almost 8% after it announced that it will receive an undisclosed milestone payment from partner Boston Pharmaceuticals related to its pipeline candidate, BOS-342 (formerly ...

We are truly blessed here in the PNW with so many useful and attractive spring blooming botanical treasures. These early ...

My first spring catalog has come. The excitement at our house is at a winter high — thinking of all of the green that comes with spring and the opportunities to add to my landscape. I have marked ...

AstraZeneca has sailed away from a licensing deal for Pieris Pharmaceuticals’ asthma med, forcing the biotech to begin charting a new corporate course and lay off 70% of its staff in the process. The ...

AstraZeneca has terminated a partnership with Pieris Pharmaceuticals on respiratory drug candidate elarekibep, forcing the latter to slash staff and look into its “strategic options”. AZ bought into ...

Pieris Pharmaceuticals is trimming the fat, putting its lead immuno-oncology asset on the chopping block to make more room for its AstraZeneca partnership. With the readout for the ...

Pieris received a grant of $17 million from the Bavarian Ministry of Economic Affairs for a drug to treat lung scarring in COVID sufferers. Shares of Pieris Pharmaceuticals (PIRS) jumped on Friday ...

In response to the company's new collaboration deal, shares of Pieris Pharmaceuticals (NASDAQ: PIRS), a clinical-stage biotech focused on cancer and other diseases, jumped as much as 16% in early ...

Pieris Pharmaceuticals’ long-standing immuno-oncology alliance with Servier is being dissolved after a clinical trial of the lead drug in the alliance revealed a safety concern. In a Securities & ...